The Efficacy and Safety Profile of Netarsudil 0.02% in Glaucoma Treatment: Real-World Outcomes by Shiuey, MS, Eric et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Phase 1 Class of 2022 
1-2020 
The Efficacy and Safety Profile of Netarsudil 0.02% in Glaucoma 
Treatment: Real-World Outcomes 
Eric Shiuey, MS 
Thomas Jefferson University, eric.shiuey@jefferson.edu 
Melih Ustaoglu, MD 
Carina Sanvicente, MD 
Reza Razeghinejad, MD 
Thomas Jefferson University, mohammadreza.razeghinejad@jefferson.edu 
L. Jay Katz, MD 
See next page for additional authors Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2022_phase1 
 Part of the Ophthalmology Commons, and the Translational Medical Research Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Shiuey, MS, Eric; Ustaoglu, MD, Melih; Sanvicente, MD, Carina; Razeghinejad, MD, Reza; Katz, MD, 
L. Jay; Myers, MD, Jonathan; and Lee, MD, Daniel, "The Efficacy and Safety Profile of Netarsudil 
0.02% in Glaucoma Treatment: Real-World Outcomes" (2020). Phase 1. Paper 16. 
https://jdc.jefferson.edu/si_ctr_2022_phase1/16 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more 
information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Eric Shiuey, MS; Melih Ustaoglu, MD; Carina Sanvicente, MD; Reza Razeghinejad, MD; L. Jay Katz, MD; 
Jonathan Myers, MD; and Daniel Lee, MD 
This abstract is available at Jefferson Digital Commons: https://jdc.jefferson.edu/si_ctr_2022_phase1/16 
SI/CTR Abstract 
Word count: 242/250 words 
 
The Efficacy and Safety Profile of Netarsudil 0.02% in Glaucoma Treatment: Real-
World Outcomes  
Eric Shiuey, MS; Melih Ustaoglu, MD; Carina Sanvicente, MD; M. Reza 
Razeghinejad, MD; L. Jay Katz, MD; Jonathan Myers, MD; Daniel Lee, MD* 
 
(*) indicates primary project advisor 
 
Introduction: More effective glaucoma medications are necessary as medication 
intolerance and non-adherence remain problematic. Netarsudil is a newly FDA-
approved Rho kinase inhibitor. We hypothesize that netarsudil will safely reduce 
intraocular pressure (IOP) compared to baseline even while other glaucoma 
medications are used. 
Methods: This retrospective observational study was conducted on glaucoma patients 
seen at the Wills Eye Hospital Glaucoma Service who received netarsudil 0.02% 
between March and September of 2018. Intraocular pressure (IOP, via Goldmann 
applanation tonometry) and best corrected visual acuity (BCVA, via Snellen visual 
acuity charts) comparisons between baseline and 1- and 3-month follow-up visits were 
performed using Student’s t-tests. 
Results: This study included 172 eyes of 108 patients. Compared to baseline, a 
meanSD decrease in IOP of 3.67±4.91 and 3.91±4.83 mmHg was noted at 1- and 3-
month follow-up visits, respectively (both p<0.001). No statistically significant difference 
in IOP change between patients on ≥3 and <3 glaucoma medications at month 1 was 
observed (p=0.667). Conjunctival hyperemia was the most common side effect at 
months 1 and 3 (15.7% and 23.0% of patients, respectively). Blurred vision was 
reported at 1- and 3-month follow-up (5.8% and 8.0% of patients, respectively), but no 
significant difference in BCVA was observed (p= 0.723 and 0.611, respectively).  
Discussion: With a mild side effect profile, netarsudil yielded a significant IOP 
reduction in glaucoma patients, including significant reductions in patients on ≥3 
medications. Given its efficacy and unique mechanism of action, earlier-line use of 
netarsudil may be considered.  
